Nitric oxide has diverse effects on head and neck cancer cell proliferation and glycolysis

Kokilakanit,Paopanga; Koontongkaew,Sittichai; Utispan,Kusumawadee

doi:10.3892/br.2024.1794

Nitric oxide has diverse effects on head and neck cancer cell proliferation and glycolysis

Authors:
- Paopanga Kokilakanit
- Sittichai Koontongkaew
- Kusumawadee Utispan
View Affiliations

Affiliations: Oral Biology Research Unit, Faculty of Dentistry, Thammasat University (Rangsit Campus), Khlong Luang, Pathum Thani 12120, Thailand, Department of Oral Health Science, International College of Dentistry, Walailak University, Dusit, Bangkok 10300, Thailand
Published online on: May 30, 2024 https://doi.org/10.3892/br.2024.1794
Article Number: 106
Copyright: © Kokilakanit et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycolysis is a key energy‑providing process and one of the hallmarks of cancer. Nitric oxide (NO), a free radical molecule, regulates glycolysis in various cancers. NO can alter the cell cycle and apoptosis in head and neck squamous cell carcinoma (HNSCC) cells. However, the effect of NO on glycolysis in HNSCC cells remains unresolved. The present study investigated the effects of NO on cell proliferation, glucose transporter (GLUT) gene expression and glycolytic indicators in HNSCC cell lines. Two pairs of isogenic HNSCC cell lines, HN18/HN17 and HN30/HN31, were treated with a NO donor, diethylamine NONOate (DEA‑NONOate), for 24, 48 and 72 h. Cell proliferation was assessed using MTT assay and NO concentration was measured using the Griess Reagent System. GLUT1, GLUT2, GLUT3, and GLUT4 gene expression was analyzed using reverse transcription‑quantitative PCR. Furthermore, hexokinase (HK) activity and lactate production were measured in NO‑treated cells using colorimetric assay. NO exhibited concentration‑dependent pro‑ and anti‑proliferative effects on the HNSCC cell lines. Lower NO concentrations (5‑200 µM) had pro‑proliferative effects, whereas NO >200 µM had an anti‑proliferative effect on HNSCC cells. NO (5 µM) promoted proliferation and glycolysis in HN18 cells by upregulating GLUT1 and GLUT2 gene expression and increasing HK activity and lactate levels. At 5‑20 µM, NO‑induced HN17 and HN30 cells demonstrated enhanced proliferation and GLUT2, GLUT3 and GLUT4 gene expression, whereas the glycolytic pathway was not affected. In conclusion, the present study demonstrated distinct proliferative effects of NO on HNSCC cells. NO may promote cell proliferation by stimulating glucose consumption and the glycolytic rate in HN18 cells. The effects of NO in other cell lines may be mediated by a non‑glycolysis mechanism and require further investigation.

View Figures

View References

1	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.PubMed/NCBI View Article : Google Scholar
2	Ma L and Zong X: Metabolic symbiosis in chemoresistance: Refocusing the role of aerobic glycolysis. Front Oncol. 10(5)2020.PubMed/NCBI View Article : Google Scholar
3	Visioli F, Wang Y, Alam GN, Ning Y, Rados PV, Nor JE and Polverini PJ: Glucose-regulated protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS One. 9(e101053)2014.PubMed/NCBI View Article : Google Scholar
4	Warburg O: The metabolism of carcinoma cells. J Cancer Res. 9:148–163. 1925.
5	Szablewski L: Glucose transporters as markers of diagnosis and prognosis in cancer diseases. Oncol Rev. 16(561)2022.PubMed/NCBI View Article : Google Scholar
6	Holman GD: Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pflugers Arch. 472:1155–1175. 2020.PubMed/NCBI View Article : Google Scholar
7	Gould GW and Holman GD: The glucose transporter family: Structure, function and tissue-specific expression. Biochem J. 295 (Pt 2):329–341. 1993.PubMed/NCBI View Article : Google Scholar
8	Barbosa AM and Martel F: Targeting glucose transporters for breast cancer therapy: The effect of natural and synthetic compounds. Cancers (Basel). 12(154)2020.PubMed/NCBI View Article : Google Scholar
9	Ding X, Liu J, Liu T, Ma Z, Wen D and Zhu J: miR-148b inhibits glycolysis in gastric cancer through targeting SLC2A1. Cancer Med. 6:1301–1310. 2017.PubMed/NCBI View Article : Google Scholar
10	Gou Q, Dong C, Jin J, Liu Q, Lu W, Shi J and Hou Y: PPARα agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway. Eur J Pharmacol. 863(172664)2019.PubMed/NCBI View Article : Google Scholar
11	Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X and Chen J: GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 78:86–94. 2018.PubMed/NCBI View Article : Google Scholar
12	Yu M, Yongzhi H, Chen S, Luo X, Lin Y, Zhou Y, Jin H, Hou B, Deng Y, Tu L and Jian Z: The prognostic value of GLUT1 in cancers: A systematic review and meta-analysis. Oncotarget. 8:43356–43367. 2017.PubMed/NCBI View Article : Google Scholar
13	Simpson IA, Dwyer D, Malide D, Moley KH, Travis A and Vannucci SJ: The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab. 295:E242–E253. 2008.PubMed/NCBI View Article : Google Scholar
14	Libby CJ, Gc S, Benavides GA, Fisher JL, Williford SE, Zhang S, Tran AN, Gordon ER, Jones AB, Tuy K, et al: A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1. Cell Adh Migr. 15:101–115. 2021.PubMed/NCBI View Article : Google Scholar
15	He Z, Chen D, Wu J, Sui C, Deng X, Zhang P, Chen Z, Liu D, Yu J, Shi J, et al: Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages. Arch Biochem Biophys. 702(108838)2021.PubMed/NCBI View Article : Google Scholar
16	Ali A, Levantini E, Fhu CW, Teo JT, Clohessy JG, Goggi JL, Wu CS, Chen L, Chin TM and Tenen DG: CAV1-GLUT3 signaling is important for cellular energy and can be targeted by atorvastatin in non-small cell lung cancer. Theranostics. 9:6157–6174. 2019.PubMed/NCBI View Article : Google Scholar
17	Pliszka M and Szablewski L: Glucose Transporters as a target for anticancer therapy. Cancers (Basel). 13(4184)2021.PubMed/NCBI View Article : Google Scholar
18	Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C and Cramer T: Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 132:21–31. 2009.PubMed/NCBI View Article : Google Scholar
19	Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia Mde L, Medina RA, Carrasco M, Barberis S, Castro T, et al: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol. 207:614–627. 2006.PubMed/NCBI View Article : Google Scholar
20	Masters C: Cellular differentiation and the microcompartmentation of glycolysis. Mech Ageing Dev. 61:11–22. 1991.PubMed/NCBI View Article : Google Scholar
21	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12(152)2013.PubMed/NCBI View Article : Google Scholar
22	Lopez-Sanchez LM, Aranda E and Rodriguez-Ariza A: Nitric oxide and tumor metabolic reprogramming. Biochem Pharmacol. 176(113769)2020.PubMed/NCBI View Article : Google Scholar
23	Mintz J, Vedenko A, Rosete O, Shah K, Goldstein G, Hare JM, Ramasamy R and Arora H: Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines (Basel). 9(94)2021.PubMed/NCBI View Article : Google Scholar
24	Choudhari SK, Chaudhary M, Bagde S, Gadbail AR and Joshi V: Nitric oxide and cancer: A review. World J Surg Oncol. 11(118)2013.PubMed/NCBI View Article : Google Scholar
25	Selvido ID, Koontongkaew S, Kokilakanit P, Sacharoen A, Korsuwannawong S and Utispan K: High nitric oxide-adapted head and neck cancer cell lines demonstrate altered autophagy and apoptosis. J Dent Sci. 19:855–864. 2024.PubMed/NCBI View Article : Google Scholar
26	Utispan K and Koontongkaew S: High nitric oxide adaptation in isogenic primary and metastatic head and neck cancer cells. Anticancer Res. 40:2657–2665. 2020.PubMed/NCBI View Article : Google Scholar
27	Li L, Zhu L, Hao B, Gao W, Wang Q, Li K, Wang M, Huang M, Liu Z, Yang Q, et al: iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. Oncotarget. 8:33047–33063. 2017.PubMed/NCBI View Article : Google Scholar
28	Cardinali M, Pietraszkiewicz H, Ensley JF and Robbins KC: Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer. 61:98–103. 1995.PubMed/NCBI View Article : Google Scholar
29	Utispan K and Koontongkaew S: Mucin 1 regulates the hypoxia response in head and neck cancer cells. J Pharmacol Sci. 147:331–339. 2021.PubMed/NCBI View Article : Google Scholar
30	Rao X, Huang X, Zhou Z and Lin X: An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
31	Ying L and Hofseth LJ: An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 67:1407–1410. 2007.PubMed/NCBI View Article : Google Scholar
32	Thomas DD, Ridnour LA, Espey MG, Donzelli S, Ambs S, Hussain SP, Harris CC, DeGraff W, Roberts DD, Mitchell JB and Wink DA: Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem. 281:25984–25993. 2006.PubMed/NCBI View Article : Google Scholar
33	Gould GW, Thomas HM, Jess TJ and Bell GI: Expression of human glucose transporters in Xenopus oocytes: Kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry. 30:5139–5145. 1991.PubMed/NCBI View Article : Google Scholar
34	Pervin S, Singh R, Hernandez E, Wu G and Chaudhuri G: Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: Involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res. 67:289–299. 2007.PubMed/NCBI View Article : Google Scholar
35	Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, et al: Nitric oxide synthase and breast cancer: Role of TIMP-1 in NO-mediated Akt activation. PLoS One. 7(e44081)2012.PubMed/NCBI View Article : Google Scholar
36	Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S and Wink DA: S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 10:1203–1215. 2012.PubMed/NCBI View Article : Google Scholar
37	Chen CL, Chang YC and Hsiao M: Rab GTPases accelerates GLUT4 translocation in colorectal cancer progression by Insulin/IGF system. FASEB J. 34:1. 2020.